Alnylam Gets $20M From Takeda

Xconomy Boston — 

Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceuticals for handing over certain RNA interference documents, materials and know-how. The payment is part of the partnership between the two companies, first formed in May 2008, which could be worth more than $1 billion over time. Alnylam is eligible to receive more milestones and royalties if Takeda translates the technology into RNAi products.